ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Abbott Buys AP214 Hormone From Action Pharma For $110 Million

DOW JONES NEWSWIRES Abbott Laboratories (ABT) took another step to enhance its renal-care pipeline by agreeing to acquire AP214, a hormone analogue that may prevent acute kidney injury during cardiac surgery, from Action Pharma A/S for $110 million in cash. The health-care company has been on a buying spree in recent years in order to reduce its dependence on the anti-inflammatory Humira as the drug's U.S. patent expires in late 2016. Abbott also is in the midst of separating into two publicly traded companies: a medical-products business and a pharmaceutical company to be named AbbVie. Abbott will acquire all global rights to develop and market AP214, and will be responsible for funding all future development and commercialization activities. No later milestone payments or royalties will be paid to the Danish biotech company Action Pharma. Abbott currently has two investigational treatments in development for chronic kidney disease: Bardoxolone, which is in Phase 3 development with Reata Pharmaceuticals, and Atrasentan, a compound discovered by Abbott being evaluated in a Phase 2b study. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stock News for Abbott Labs (ABT)
DateTimeHeadline
08/24/201609:00:00Abbott to Present at Wells Fargo Healthcare Conference
08/17/201602:09:05Aqua Bio Technology: Stable revenues, results affected by U.S...
08/09/201616:53:26Registration Statement for Securities to Be Issued in Business...
08/03/201616:35:50Quarterly Report (10-q)
08/02/201610:00:00Abbott Unveils Alinity™, its Unified Family of Innovative Next-Generation D...
07/29/201617:06:14Statement of Changes in Beneficial Ownership (4)
07/29/201617:05:18Statement of Changes in Beneficial Ownership (4)
07/29/201610:40:00AbbVie Results Boosted by Humira, Pipeline Growth
07/29/201610:31:00AbbVie Results Boosted by Humira, Pipeline Growth
07/28/201608:10:00China's Fosun Close to Deal for India's Gland Pharma
07/28/201603:03:00Alere Faces Criminal Probe Over Billing -- WSJ
07/27/201618:57:00Alere Faces Criminal Probe Over Medicare, Medicaid Billing...
07/27/201617:14:00Alere Faces Criminal Probe Over Medicare, Medicaid Billing...
07/27/201617:10:00Alere Faces Criminal Probe Over Medicare, Medicaid Billing
07/27/201616:45:54Statement of Changes in Beneficial Ownership (4)
07/27/201616:45:04Statement of Changes in Beneficial Ownership (4)
07/27/201616:35:00Alere Faces Criminal Probe Over Medicare, Medicaid Billing
07/27/201616:32:01Statement of Changes in Beneficial Ownership (4)
07/27/201616:31:09Statement of Changes in Beneficial Ownership (4)
07/27/201616:31:09Statement of Changes in Beneficial Ownership (4)

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad